Clinical Relevance of EGFR- or KRAS-mutated Subclones in Patients With Advanced Non-small-cell Lung Cancer Receiving Erlotinib in a French Prospective Cohort (IFCT ERMETIC2 Cohort - Part 2).

Date publication

décembre 2018

Journal

Clinical lung cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle , Dr LIZARD Sarab

Tous les auteurs :
Beau-Faller M, Texier M, Blons H, Richard N, Escande F, Melaabi S, Lizard S, De Fraipont F, Longchampt E, Morin F, Zalcman G, Pignon JP, Cadranel J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30679079

Résumé

Evaluation of EGFR Mutation status for the administration of EGFR-TKIs in non-small cell lung Carcinoma (ERMETIC) was a prospective study designed to validate the prognostic value of EGFR/KRAS mutations in patients with advanced non-small-cell lung cancer (NSCLC), all receiving a first-generation tyrosine kinase inhibitor, erlotinib. ERMETIC2 was an ancillary project evaluating the clinical value of common EGFR/KRAS-mutated subclones regarding prognosis using highly sensitive molecular detection methods.

Mots clés

Driver mutations, Molecular techniques, NSCLC, Sensitivity, Tyrosine kinase inhibitor

Référence

Clin Lung Cancer. 2018 Dec 19;: